strategy

Preventing cancer

Synonyms:
Preventing carcinomas
Description:

Cancer is largely avoidable.

Context:

Epidemiological evidence points to a strong correlation between diet and certain diseases such as cancer and cardiovascular disease.

Implementation:

Will the 1990s be remembered as "the decade when we measurably turned the tide against cancer"? The US study, Annual Report to the Nation on the Status of Cancer, 1973-1998 reports an annual decline of 1% per annum. Many find this conclusion misleading. Taking several factors into account, it is not clear that there has been any decrease at all. First, lung cancer, which is in no way due to medical advances, accounts for the lion's share of the cancer rate decline. Take lung cancer out of the equation, and the reported decline in cancer is cut by a third. Second, it overlooks the fact that overall cancer rates rose by more than a factor of ten during the 20th century and increasing over 20% just from 1973 to 1992. The incidences of ten other cancers have increased from 1992 to 1998. These include cancer of the liver, thyroid, oesophagus, small intestine and heart, plus non-Hodgkin's lymphoma, melanoma and breast cancer. Thirdly, certain cancer types are not counted, notably [in situ] carcinomas, which are an early stage of cancer in which the tumour is confined to the organ where it first developed. For example, breast cancer rates have increased 40% from 1975 to 1998. Not included in the statistics are incidences of two types of in situ breast cancer, one that develops in the milk passages (ductal carcinoma in situ (DCIS)) and another than develops in the milk-producing glands (lobula carcinoma in situ (LCIS). Because these tumours have not invaded neighbouring tissue, the standard treatment of surgery (lumpectomy or full mastectomy), radiation and chemotherapy is usually effective in stopping its spread. The incidence of in situ breast cancers has surged and continues to increase: The American Cancer Society estimates that 46,400 American women will have been diagnosed with DCIS or LCIS in 2001. Adding these in situ cancers to invasive breast cancers would increase the incidence rate by 24%.

Neither does the survey count in situ melanoma skin cancers, with which the American Cancer Society estimates 31,400 Americans will be diagnosed in 2001. Adding these cases would increase the rate for skin cancer by 56%.

Changes in diagnostic procedures also affect incidence rates. In explaining fluctuations in the incidence of prostate cancer, for example, the National Institutes of Health noted that with the advent of Prostate Specific Antigen (PSA) screening in the late 1980s, there was a spike in the incidence of prostate cancer, not because more men were suddenly getting the disease above the normal increase, but because previously undetected cancers were suddenly being diagnosed. Now that the prevalent cancers have been detected, what looks like a decline in incidence in the 1990s, they say, is not due to fewer men getting prostate cancer, but is a decline relative only to the abnormally high number of tests and diagnoses made just previous to that period.

Claim:

Appropriations for cancer prevention are currently minuscule and could be raised to achieve parity with diagnosis, treatment and basic research. The cancer establishment should conduct detailed studies of the wide range of avoidable and involuntary carcinogenic exposures and legislators act to remove them from the environment.

Counter Claim:

The war against cancer is an out and out failure. Despite decades of basic scientific and clinical research, and numerous trials of 'promising new medical therapies', cancer remains a major cause of sickness and death in the western world. While there have been some success in treating some forms of cancer, especially those of children and young adults, it is not stopping people getting cancer, and the effects of these benefits on overall mortality due to cancer have been more than disappointing. In 1994, death rates from all cancers were actually 6% higher than in 1970.

Constrains:
Risking cancer
Organizations:
Psycho-Oncology Society (1100021826)
on of Surgical Oncology Societies (1100019948)
Society of Paediatric Oncology (1100061971)
Association for the Study of Lung Cancer (1100037927)
ty for Hyperthermic Oncology (1100064248)
ty of Gynaecological Oncology (1100057148)
r Organisation (1100029434)
Society for Radiation Oncology (1100027632)
r Prevention Organization (1100030352)
ogy Nursing Society (1100045585)
ty of Surgical Oncology (1100031017)
Society for Nurses in Cancer Care (1100062246)
iation for Cancer Education (1100025111)
ociety for Head and Neck Oncology (1100038925)
Society for Preventive Oncology (1100048930)
ty for Therapeutic Radiology and Oncology (1100002750)
for Pediatric Hematology and Oncology (1100000372)
lo-Skeletal Oncology Society (1100017801)
Gynecologic Cancer Society (1100018738)
Union (1100034546)
for Breast Cancer Screening (1100047305)
Society for Pediatric Oncology (1100055773)
for Psychosocial Oncology (1100005005)
f European Cancer Institutes (1100051363)
Association for Hyperthermic Oncology (1100058578)
Gastric Cancer Association (1100019653)
ty for Medical Oncology (1100045997)
lioma Society (1100022810)
Society for the Study of Comparative Oncology (1100040497)
iation for Neuro-Oncology (1100058220)
Society of Cancer Prevention (1100021838)
ancer Society (1100039469)
Association of Supportive Care in Cancer (1100018808)
Cancer Imaging Society (1100028333)
f Oncology (1100035727)
ty of Skin Cancer Prevention (1100062129)
iation of Dermato-Oncology (1100063665)
of Gynecological Oncology (1100019782)
European Cancer Leagues (1100032123)
sue Oncology Society (1100038478)
for Neuro-Oncology (1100062340)
on of Neuro-Oncology (1100010147)
Society of Paediatric Surgical Oncology (1100063586)
ation of Psychosocial Oncology Societies (1100021361)
Cancer Information Center (1100060391)
Academy of Tumor Marker Oncology (1100027523)
Brachytherapy and Radiation Oncology Group (1100015562)
Campaign for Establishment and Development of Oncology Centres (1100015128)
Cancer Working Party (1100015485)
l of Oncology (1100029532)
The European Breast Cancer Coalition (1100050875)
ervical Cancer Prevention (1100043837)
Cancer Microenvironment Society (1100018114)
Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer (1100038979)
Alliance of Breast Cancer Organizations (1100040379)
Bladder Cancer Network (1100023921)
r Centre for Developmental and Supportive Therapy (1100019174)
School of Surgical Oncology, Strasbourg (1100007875)
Cancer League (1100027382)
tute of Oncology, Milan (1100030304)
Concern, India (1100022310)
Concern, UK (1100009296)
Association for Hormones and Cancer (1100062576)
Institute of Advanced Therapy for AIDS and Cancer (1100014439)
cademy for Cancer Biotherapy (1100043456)
ssociation Against Cancer (1100004501)
l of Oncology Foundation (1100057541)
Cancer Programme (1100004543)
Association of Cancer Victors and Friends (1100062317)
Cancer Alliance for Research and Education (1100020063)
for Colorectal Cancer Screening (1100036517)
r Centre (1100009968)
ntie voor Complementaire Kankerbestrijding (1100044450)
for Hyperthermic Oncology (1100030671)
rnationale d'applications au cancer et sida (1100020366)
Conference on the Adjuvant Therapy of Cancer (1100018393)
Epidemiological Unit (1100062343)
Cancer Chemotherapy Society (1100015649)
Clinical Oncology Association (1100039497)
n Plan Against Cancer (1100065675)
internationale de recherches contre la tuberculose et le cancer (1100055129)
Type Classification:
C: Cross-sectoral strategies
Related UN Sustainable Development Goals:
GOAL 3: Good Health and Well-beingGOAL 15: Life on Land